middle.news
Mesoblast Prepares FDA Talks on Rexlemestrocel-L’s Opioid Cessation Promise
10:21am on Wednesday 5th of November, 2025 AEDT
•
Healthcare
Read Story
Mesoblast Prepares FDA Talks on Rexlemestrocel-L’s Opioid Cessation Promise
10:21am on Wednesday 5th of November, 2025 AEDT
Key Points
FDA meeting scheduled for early December 2025
Phase 3 trial shows over threefold increase in opioid cessation with rexlemestrocel-L
Confirmatory 300-patient Phase 3 trial underway in the US
Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy (RMAT) designation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MSB
OPEN ARTICLE